A llogeneic hematopoietic stem cell transplant (HSCT) is considered the most effective therapy to provide long term leukemia free survival in high-risk acute myeloid leukemia (AML). The therapeutic options for a relapsed AML are few and the underlying mechanism of immune escape for recurring relapse is not well understood. 1 Isolated vulvar myeloid sarcoma as an extramedullary relapse of leukemia is a very rare condition. Complete remission can be achieved with chemotherapy and there is a limited role for surgical intervention. The following report is presented in view of its rarity and discussed in light of the available literature.
myeloid sarcoma is a tumor of myoblasts or immature myeloid cells occurring in an extramedullary site. myeloid sarcoma of the female genital tract as an isolated initial presentation or isolated relapse is very rare as evidenced from a literature review. We report a case of vulvar myeloid sarcoma presenting as isolated relapse of acute myeloid leukemia (amL) after allogeneic hematopoietic stem cell transplant (hsCt). a 41-year-old female diagnosed with amL m5 achieved remission with chemotherapy and underwent allogeneic hsCt from an hLa-matched sibling donor. the post-transplant period was complicated with chronic graft-versus-host disease. at 10 months post-transplant, she presented with a vulvar mass of six weeks duration. Excisional biopsy of the vulvar mass confirmed the diagnosis of myeloid sarcoma as extramedullary relapse. Bone marrow biopsy was without evidence of leukemia. involvement of the vulva, vaginal and adjacent cervical area only was confirmed. she received re-induction chemotherapy with clinical regression of both the vulvar, vaginal and the cervical masses; this was followed by radiation therapy to an extramedullary site. the correct diagnosis of myeloid sarcoma, particularly of an isolated mass in the genital area, is important because of its rarity and the need for appropriate institution of therapy. 2010 complaining of easy fatigability and dizziness. A complete evaluation revealed an initial WBC count of 120×10 9 /L with myeloid blasts and a bone marrow examination consistent with acute myeloid leukemia (AML M5) and normal cytogenetics. She received induction chemotherapy with idarubicin 12 mg/m 2 ×3 days, cytarabine 100 mg/m 2 continuous infusion for 7 days and etoposide 100 mg/m 2 ×5 days (ICE). Day 14 bone marrow examination revealed refractory leukemia. She received salvage chemotherapy consisting of the mitoxantrone, etoposide and cytarabine (MEC) protocol. On day 28 of salvage chemotherapy, she achieved complete hematological remission with no evidence of bone marrow infiltration of leukemic cells. The patient was referred to our hospital for allogeneic HSCT from an HLA-matched sister. She underwent allogeneic peripheral blood HSCT in August 2010 with a myeloab-lative conditioning regimen of busulfan and cyclophosphamide (BU-CY2). The post-transplant period was complicated by development of chronic GVHD with involvement of skin, oral mucosa, eyes and weight loss. She was treated with cyclosporine and prednisone with a fairly good response. On regular follow up in May 2011, she presented with a right vulvar mass lesion of 6-weeks duration. There was no abnormal vaginal bleeding or pelvic pain. She was referred to the gynecological clinic for further evaluation. On examination, there was 2×2 cm tender mass on the right vulva and the initial impression was Bartholine cyst. She underwent examination under anesthesia and vulvar mass excisional biopsy. After complete dissection of the mass from adjacent vulvar tissue, a gray mass measuring 2×1.5×1.5 cm was sent for histopathology. The result confirmed myeloid sarcoma. Further evaluation with MRI pelvis showed intermediate signal intensity soft tissue mass circumferentially surrounding the cervix and vagina as well as urethra with intact fibrous stromal tissue. This soft tissue mass was invading the parametrium with involvement of the labia minora. Bone marrow biopsy showed no evidence of leukemia at this time. The diagnosis of relapse of isolated extramedullary leukemia was made. She underwent re-induction chemotherapy with an intermediate dose of cytarabine 1.5 g/m 2 every 12 hours for 6 doses, followed by radiation therapy to the area of the cervical, vaginal and vulvar mass for a total dose of 2000 CGy. CT scan repeated one month after treatment showed complete resolution of the vulvar, vaginal and cervical mass. She remained in complete remission on follow up.
In February 2012, the patient was admitted to the hospital for evaluation of a right breast mass accompanied with persistent headache. Ultrasound of the breast showed a small breast mass at 10 o' clock. Biopsy was consistent with myeloid sarcoma. The bone marrow showed no evidence of leukemia. The result of the CSF examination confirmed CNS leukemia. For the CNS involvement, she received intrathecal chemotherapy and 12 fractions of cranial radiation therapy up to the C2 level for a total dose of 2400 CGy. Radiation therapy was also given for the breast mass for a total of 2400 CGy. The overall management at this stage of extensive multiple site extramedullary relapse was palliation and comfort care.
DISCuSSIOn
Extramedullary relapse after HSCT for AML is a rare event and is less well defined than systemic, hematologic relapse. Myeloid sarcoma involving the gynecologic tract, prompting surgical biopsy or excision, is uncommon. As described in the literature, most patients also have evidence of AML or a myelodysplastic or myeloproliferative neoplasm diagnosed in the past or virtually simultaneously with the diagnosis of myeloid sarcoma.
Histologically, the diagnosis of myeloid sarcoma can be challenging to surgical pathologists when the neoplasm is found in an unusual location, particularly when the neoplastic cells are immature or when myeloid sarcoma occurs in the absence of any other evidence of AML. The rate of misdiagnosis (including incomplete and incorrect diagnoses) for cases of myeloid sarcoma reported in the literature is appreciable, although it is much lower in the era of immunohistochemical analysis. In our case, immunohistochemical staining and immunophenotypic analysis confirmed extramedullary leukemia (myeloid sarcoma) ( Table 1) .
In our review of the literature, we found 50 cases of myeloid sarcoma of the gynecologic tract reported with a history of AML and only two cases where the vulva was primarily involved. The first one was reported by Erşahin et al 2 of a 73-year-old patient with a previous history of AML. Isonishi et al 3 reported a case of a 21-year-old female with isolated vulvar myeloid sarcoma. She was treated with chemotherapy and bone marrow transplant, but she developed acute myeloid leukemia after complete remission.
Twenty-eight patients with isolated myeloid sarcoma of the female genital tract are reported in the literature and they were treated with different management protocols. Complete remission and a report of a 10-year remission were achieved with chemotherapy ( Table 2) 4 and none of the patients were treated with hysterectomy or salpingo-oophorectomy.
Allogeneic HSCT is considered a curative treatment for various malignant hematological disorders including AML. One of the major causes of mortality after allogeneic HSCT is relapse of the disease. Several factors affect the outcome, including disease status at the time of transplant, histology, chemotherapy sensitivity, type of allograft and conditioning regimen. Treatment of relapsed disease is also affected by different factors including disease status at the time of relapse. The treatment mainstay is donor lymphocyte infusion, but also includes chemotherapy and second alloHSCT. 5 A recent study examined the incidence and risk factors for extramedullary (EM) and bone marrow (BM) relapse. Genitourinary EM relapse was rare. The time-to-relapse in the EM sites was longer and patients were more likely to have had chronic GVHD. The survival after EM relapse was reported to be better and improved outcome with systemic therapy. 6 Our patient presented with EM relapse 10 months after allogeneic HSCT and had chronic GVHD for 6 months. She responded to the combined therapy and remained alive on recent follow up.
We have recently described a pattern of relapse in 601 patients who received an allogeneic HSCT at our institution for acute or chronic leukemia and myelodysplasia over a period of 18 years. We showed a correlation between chronic GVHD and extramedullary relapse, suggesting that the expected graft-versus-leukemia effect in patients with chronic GVHD may preferentially maintain marrow remission without preventing relapse in extramedullary sites. 7 In conclusion, the diagnosis and the management of myeloid sarcoma of the female genital tract, because of its rarity, is challenging for both the anatomic pathologist and the oncologist. In a subset of patients, systemic therapy can induce complete remission and long-term survival. Development of GVHD has an effect on the occurrence and outcome of relapse. There seems to be a better protection for the BM site than in patients who did not develop GVHD. The outcome for overall survival is better in EM relapse with combined therapy as compared to BM relapse.
